Full-Time

Director – Clinical Assay Development

Posted on 11/7/2024

Alamar Biosciences

Alamar Biosciences

51-200 employees

Develops technology for protein detection and measurement

Biotechnology
Healthcare

Compensation Overview

$200k - $220kAnnually

+ Bonus + Equity

Expert

Fremont, CA, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Required Skills
Data Science
Data Analysis

You match the following Alamar Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Ph.D. or equivalent in molecular biology, biochemistry, immunology or a related field
  • 14+ years working in life science/diagnostic industry with a track record of clinical-grade immunoassay development
  • In-depth knowledge of industry standards including CLSI guidelines related to immunoassays
  • Multiplex clinical immunoassay development experience is highly desirable.
  • Hands-on experience with qPCR and/or NGS molecular assay development a plus
  • Experience in IVD product development and regulatory submissions
  • Proven leadership in building and growing technical teams
  • Strong communicator within and outside of the Company
  • Strong organizational skills and ability to adapt to shifting priorities
Responsibilities
  • Lead clinical assay development from feasibility to clinical evaluation studies according to Company design control process
  • Provide leadership and technical expertise in experimental design, execution and data analysis following CLSI guidelines
  • Ensure robust clinical performance by conducting assay optimization, stability testing, interference testing, etc.
  • Draft technical documents and reports to support regulatory submissions
  • Provide expert leadership in troubleshooting and assay optimization
  • Work closely with biostatistics/data science groups to align study designs and acceptance criteria
  • Build and manage team by coaching and fostering teamwork
  • Collaborate across company to contribute to strategic direction and ensure product meets technical and business criteria
  • Collaborate with external key opinion leaders in assay development and validation
Desired Qualifications
  • Multiplex clinical immunoassay development experience is highly desirable.
  • Hands-on experience with qPCR and/or NGS molecular assay development a plus

Alamar Biosciences focuses on the study of proteins, known as proteomics, to enhance disease detection and treatment. The company's main product, NULISA™, allows for the detection and measurement of proteins in the human body with high sensitivity and a wide range. This technology helps researchers and clinicians identify clinically relevant protein biomarkers, which are crucial for developing new diagnostic tests and treatments. Alamar's ARGO™ system complements NULISA™ by providing a fully automated platform for high-throughput precision proteomics, enabling users to analyze multiple protein targets in a single experiment. Unlike competitors, Alamar's technology simplifies the process, reducing the need for extensive technical expertise, making it accessible to a broader range of clients. The goal of Alamar Biosciences is to improve our understanding of proteins in health and disease, ultimately leading to better early detection and treatment options for various diseases.

Company Stage

Grant

Total Funding

$225.7M

Headquarters

Hayward, California

Founded

2018

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Alamar's expansion into the APAC region enhances its global commercial presence.
  • The $10M investment for Alzheimer's diagnostics boosts Alamar's precision medicine capabilities.
  • Collaboration with The Michael J. Fox Foundation advances Parkinson's research and biomarker discovery.

What critics are saying

  • Emerging competition from companies like Olink Proteomics could challenge Alamar's market position.
  • Potential regulatory hurdles in the APAC region may delay ARGO™ HT System deployment.
  • High development costs of proteomics technology could strain Alamar's financial resources.

What makes Alamar Biosciences unique

  • Alamar's NULISA™ technology offers unprecedented sensitivity in protein detection and measurement.
  • The ARGO™ system provides a fully automated, high-throughput precision proteomics platform.
  • NULISAseq™ Inflammation Panel AQ sets a new standard in immune response profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

401(k) Retirement Plan

Performance Bonus

Company Equity

INACTIVE